ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0307 • ACR Convergence 2025

    Cytokine Profiling of Molecular Endotypes of Knee Osteoarthritis: Insights from the IMI-APPROACH cohort

    Monica T. Hannani1, Jaume Bacardit2, Jonathan Larkin3, Virpi Glumoff3, Morten A. Karsdal1, Anne-Christine Bay-Jensen1, Ali Mobasheri3 and Christian Thudium4, 1Nordic Bioscience A/S, Herlev, Denmark, 2Newcastle University, Newcastle upon Tyne, United Kingdom, 3University of Oulu, Oulu, Finland, 4Nordic Bioscience, Herlev, Denmark

    Background/Purpose: There has been a surging interest in characterizing subpopulations of osteoarthritis (OA) to facilitate recruitment of the right subgroups for drug development. The APPROACH…
  • Abstract Number: 0325 • ACR Convergence 2025

    Knee Symptom Phenotyping Incorporating Pain and Function across Different Levels of WOMAC Function in Two Cohorts: Data from the Multicenter Osteoarthritis Study (MOST) and the Osteoarthritis Initiative (OAI)

    C. Kent Kwoh1, Amanda Nelson2, Rongrong Tang3, Edward J. Bedrick3, Yong Ge1, Yvonne Golightly4, Zong-Ming Li3, Jean Liew5, Xiaoxiao Sun1, Jeffrey Duryea6 and Tuhina Neogi5, 1The University of Arizona Arthritis Center, University of Arizona, Tucson, AZ, 2University of North Carolina at Chapel Hill, Chapel Hill, NC, 3The University of Arizona Arthritis Center, University of Arizona, Tucson, 4University of Nebraska Medical Center, Omaha, NE, 5Boston University School of Medicine, Boston, MA, 6Brigham and Women’s Hospital, Boston, MA

    Background/Purpose: Knee pain and functional limitations are the most common symptoms of knee OA. Understanding the various patterns of symptoms (i.e., pain and function changes…
  • Abstract Number: 0357 • ACR Convergence 2025

    Content validation of patient-reported outcome (PRO) measures for fatigue, physical function and disease activity in Polymyositis (PM)

    Jason Xenakis1, Esther Yi1, Iyar Mazar2, Sarah Knight3, Harriet Makin3, Samantha Wratten3, Rohit Aggarwal4 and Stephanie McKee3, 1Pfizer Inc., New York, United States of America, New York, 2Pfizer, US, New York, 3Clarivate, London, United Kingdom, 4University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA

    Background/Purpose: Polymyositis (PM) is a subtype of idiopathic inflammatory myopathy (IIM) characterized by muscle inflammation and muscle weakness. Extra muscular manifestations like interstitial lung disease…
  • Abstract Number: 0330 • ACR Convergence 2025

    Prevalence of Radiographic and Symptomatic Osteoarthritis, and Ultrasound Features at the Knee: The Johnston County Health Study

    Maya Patel1, Carolina Alvarez2, Todd Schwartz3, Tessa Walker1, Serena Savage-Guin1, Jordan Renner1, Jonathan Samuels4, Janice Lin5, Minna Kohler6, Catherine Bakewell7, Yvonne Golightly8 and Amanda Nelson1, 1University of North Carolina at Chapel Hill, Chapel Hill, NC, 2University of North Carolina at Chapel Hill, Miami, FL, 3University of North Carolina-Chapel Hill, Chapel Hill, NC, 4NYU Langone, Rye Brook, NY, 5Stanford University, Palo Alto, CA, 6Massachusetts General Hospital, Harvard Medical School, Boston, MA, 7Intermountain Healthcare, Salt Lake City, UT, 8University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: To report sex and BMI differences among ultrasound (US) features of knee osteoarthritis (KOA), patient-reported symptoms (Ksx), radiographic KOA (rKOA), and symptomatic KOA (sxKOA),…
  • Abstract Number: 0372 • ACR Convergence 2025

    Development and Implementation of a Remote Educational Program to Optimize Safe Medication Use in Older Veterans with Rheumatic Diseases

    Maria Romero Noboa1, Hannah Howell2, Angelo Gaffo3 and Maria I. ("Maio") Danila4, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, 3Division of Rheumatology and Clinical Immunology, University of Alabama, Birmingham, AL, USA; Birmingham VA Medical Center, Birmingham, AL, USA, Birmingham, AL, 4University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL

    Background/Purpose: Symptomatic treatment in rheumatic and musculoskeletal diseases (RMDs) – including glucocorticoids (GCs) and non-steroidal anti-inflammatory drugs (NSAIDs) – can result in improved quality of…
  • Abstract Number: 0389 • ACR Convergence 2025

    An International Delphi Survey for the Definition of New Classification Criteria for Juvenile Idiopathic Arthritis

    Alessandra Alongi1, Hermine Brunner2, Angelo Ravelli3, Tadej Avcin4, Michael Beresford5, RUBEN BURGOS-VARGAS6, Ruben Cuttica7, Raju Khubchandani8, Ronald laxer9, Seza Özen10, Ross Petty11, Carol Wallace12, Nico Wulffraat13, Silvia Magni-Manzoni14, Marija Jelusic15, Alessandro Consolaro16, Jordi anton17, Gerd Horneff18, Mia Glerup19, Giovanni Filocamo20, Gabriele Simonini21, ADELE CIVINO22, Agustin Remesal23, Silvia Scala24, Angela Pistorio25, Daniel Lovell2, Alberto Martini26 and Nicolino Ruperto27, 1Università Milano Bicocca, Milan, Italy, Milano, Italy, 2Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3IRCCS Istituto Giannina Gaslini, Genoa, Italy, Genoa, Genoa, Italy, 4University Children's Hospital, University Medical Center Ljubljana, Ljubljana, Slovenia, 5Alder Hey Children's NHS Foundation Trust Hospital, Department of Women's & Children's Health, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, United Kingdom, 6Department of Rheumatology, Hospital General de Mexico, Faculty of Medicine, Universidad Nacional Autonoma de Mexico, Ciudad de México, Mexico, 7Hospital Pedro de Elizalde, Buenos Aires, Argentina, 8Jaslok Hospital and Research Center, Mumbai, India, 9The Hospital for Sick Children, Toronto, ON, Canada, 10Hacettepe University Medical Faculty, Ankara, Turkey, 11British Columbia Children’s Hospital, University of British Columbia, Vancouver, ON, Canada, 12Seattle Children's Hospital, University of Washington, Seattle, WA, 13Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, Netherlands, 14Bambino Gesù IRCCS Children's Hospital, Rome, Italy, 15University Hospital Centre Zagreb, Zagreb, Croatia, 16IRCCS Istituto Giannina Gaslini, Genoa, Italy, 17Hospital Sant Joan de Düu. Universitat de Barcelona, Barcelona, Spain, 18Asklepios Klinik, Hamburg, Germany, 19Department of Paediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark, 20Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, 21Rheumatology Unit, ERN-ReCONNET center, Meyer Children's Hospital IRCCS, Firenze, Firenze, Italy, 22Department of Pediatric Immunology and Rheumatology, LECCE, Italy, 23Hospital Universitario La Paz, Madrid, Spain, 24Clinica Pediatrica e Reumatologia, IRCCS Istituto Giannina Gaslini, Genoa, Italy, 25Servizio di Epidemiologia e Biostatistica, IRCCS Istituto Giannina Gaslini, Genoa, Italy, 26Università degli Studi di Genova, IRCCS Istituto Giannina Gaslini, Genoa, Italy, 27Université Milano Bicocca and Fondazione IRCSS S. Gerardo dei Tintori, Monza, Monza and Brianza, Italy

    Background/Purpose: To improve the current classification criteria for juvenile idiopathic arthritis (JIA), a multi-step initiative coordinated by PRINTO was launched in 2015, starting with a…
  • Abstract Number: 0358 • ACR Convergence 2025

    Different Perspectives between Physicians and Patients on Treatment Priorities and Challenges in Still’s Disease

    Gisella Beatrice Beretta1, Luciana Pereira2, Greta Rogani3, Francesco Baldo4, Claudia Bracaglia5, Dirk Foell6, Marco Gattorno7, Marija Jelusic8, Sebastiaan Vastert3, Rashmi Sinha9 and Francesca Minoia10, 1Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy, Milan, Italy, 2Systemic JIA Foundation, Cincinnati, 3University Medical Center Utrecht, Utrecht, Utrecht, Netherlands, 4ASST-Pini-CTO, Milano, Milan, Italy, 5IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Rome, Italy, 6University Hospital Muenster, Muenster, Germany, 7IRCCS G. Gaslini, Genova, Genoa, Italy, 8University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Zagreb, Croatia, 9Systemic JIA Foundation, Cincinnati, OH, 10Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Milan, Italy

    Background/Purpose: Despite therapeutic advances, major concerns and disparities persist in the care of Still’s Disease (SD). Capturing both patient/caregiver and physician perspectives is essential to…
  • Abstract Number: 0378 • ACR Convergence 2025

    Identifying Patterns of Telemedicine Readiness and Digital Health Literacy in Rheumatoid Arthritis Patients: A Latent Class Analysis

    Preeti Dhanasekaran1, Bryant Lim2, Qai Ven Yap2, Hafizah Ahmad3, Siew Hwa Chong3, Ginny Goh3, Manjari Lahiri4, Amelia Santosa4, Gim Gee Teng3, Peter Cheung4, Siriwan Lim1 and Margaret Ma4, 1National University of Singapore, Singapore, Singapore, 2National University of Singapore, Singapore, 3National University Hospital, Singapore, 4National University Hospital, Singapore, Singapore

    Background/Purpose: The COVID-19 pandemic accelerated telemedicine adoption, yet readiness and digital literacy vary widely across patient populations. Understanding these differences is crucial to designing equitable…
  • Abstract Number: 0321 • ACR Convergence 2025

    Per- and Polyfluoroalkyl Substances and Hand Osteoarthritis: Data from the Osteoarthritis Initiative

    Jeffrey Driban1, Lisa Rokoff2, Bing Lu3, Timothy McAlindon4, Charles Eaton5, Mary Roberts6, Diana Mathes7, Colleen Lestician7, Zhijin Carrie Xu7, Zhihua Tina Fan7, Shawn O'Leary7 and Abby Fleisch8, 1University of Massachusetts Chan Medical School, Marlborough, NH, 2Center for Interdisciplinary and Population Health Research, MaineHealth Institute for Research, Westbrook, ME, 3UConn Health Center, Newton, MA, 4UMass Chan School of Medicine, Arlington, MA, 5Brown University, Pawtucket, RI, 6Center for Primary Care and Prevention, Kent Hospital, Pawtucket, RI, 7Environmental and Chemical Laboratory Services, Public Health & Environmental Laboratories, New Jersey Department of Health, Ewing, NJ, 8Maine Medical Center; 2. Center for Interdisciplinary and Population Health Research, MaineHealth Institute for Research, Westbrook, ME

    Background/Purpose: The prevalence of hand osteoarthritis (OA) has doubled in the United States over the past half century – a finding that cannot be solely…
  • Abstract Number: 0407 • ACR Convergence 2025

    The SOS project: to Switch Or to Swap After Adalimumab failure for the management of childhood non-infectious uveitis in an international cohort

    Ilaria Maccora1, Margaret Chang2, Sheila Angeles-Han3, Andrea Taddio4, Lampros Fotis5, Cinzia de Libero6, Madison Mangin7, Alexandra Duell8, Marco Gabrielli9, Kyveli Chiotopoulou5, Lillian Sutton10, Virginia Miraldi Utz8 and Gabriele Simonini11, 1Rheumatology Unit, ERN ReCoNNET Center, Meyer Children's Hospital IRCCS, Florence, Italy, Firenze, Florence, Italy, 2Boston Children's Hospital, Boston, MA, 3Cincinnati Children's Hospital, Cincinnati, OH, 4Insitute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy, 5Division of Pediatric Rheumatology, Department of Pediatrics, ATTIKON General Hospital, National and Kapodistrian University of Athens, Greece, Athene, Greece, 6Ophthalmology Unit, Meyer Children's Hospital IRCCS, Florence, Italy, Florence, Italy, 7Boston Children's Hospital, St Simons Island, GA, 8Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 9University of Trieste, Trieste, Italy, Trieste, Italy, 10Division of Immunology, Boston Children’s Hospital, Boston, MA, USA, Boston, 11Rheumatology Unit, ERN-ReCONNET center, Meyer Children's Hospital IRCCS, Firenze, Firenze, Italy

    Background/Purpose: Childhood chronic non-infectious uveitis (cNIU) is a sight-threatening condition that can lead to blindness if not appropriately treated. cNIU is typically associated with Juvenile…
  • Abstract Number: 0305 • ACR Convergence 2025

    From Movement to Meaning: Exploring Physical Function in IBM with Actigraphy

    Vaidehi Kothari1, Eaman Alhassan2, Kevin Renz Ambrocio1, Bonny Rockette-Wagner3, Chester V. Oddis1, Kendrea (Focht) Garand1 and Rohit Aggarwal4, 1University of Pittsburgh, Pittsburgh, PA, 2University of Pittsburgh Medical Center, Pittsburgh, PA, 3University of Pittsburgh, PITTSBURGH, 4University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA

    Background/Purpose: Inclusion body myositis (IBM) is a progressive and severe inflammatory muscle disease that primarily affects adults over 50 years of age. It presents with…
  • Abstract Number: 0398 • ACR Convergence 2025

    Efficacy of Tumor Necrosis Factor Inhibitors in Children Diagnosed With Non-Systemic Juvenile Idiopathic Arthritis ≤ 2 Years Old Using The Childhood Arthritis and Rheumatology Research Alliance Registry

    Christina Gulla1, Tara Lozy2 and Ginger Janow3, 1Hackensack University Medical Center, Hackensack, NJ, 2Joseph M. Sanzari Children's Hospital, Center for Discovery and Innovation, Hackensack Meridian School of Medicine, Nutley, 3Joseph M. Sanzari Children's Hospital at Hackensack Meridian Health, Hackensack, NJ

    Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common pediatric rheumatic disease. Tumor necrosis factor inhibitors (TNFi) are key treatments in non-systemic JIA (sJIA), but…
  • Abstract Number: 0403 • ACR Convergence 2025

    IL-6 as a Predictor of Response to Olokizumab in Polyarticular-Course Juvenile Idiopathic Arthritis: Results of the Phase 2 Clinical Trial

    Ekaterina Alexeeva1, Tatiana Dvoryakovskaya1, Elena Zholobova2, Elizaveta Krekhova3, Valeria Matkava4, Rinat Raupov5, Daria Bukhanova6, Alina Egorova6, Sergey Grishin6, Mikhail Samsonov6, Mikhail Kostik7 and Irina Nikishina4, 1National Medical Research Center for Children’s Health Federal State Autonomous Institution of the Russian Federation Ministry of Health and I.M. Sechenov First Moscow State Medical University (Sechenovskiy University), Moscow, Russia, 2I.M.Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia, 3National Medical Research Center for Children’s Health Federal State Autonomous Institution of the Russian Federation Ministry of Health, Moscow, Russia, 4V.A.Nasonova Research Institute of Rheumatology, Moscow, Russia, 5H.Turner National Medical Research Center for Childrens Orthopaedics and Trauma Surgery, Saint-Petersburg, Russia, 6R-Pharm JSC, Moscow, Russia, 7Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia

    Background/Purpose: Olokizumab (OKZ) is a direct interleukin-6 (IL-6) inhibitor. IL-6 is an attractive target for the treatment of pJIA. The aim of the study was…
  • Abstract Number: 0408 • ACR Convergence 2025

    Implementing Social Drivers of Health Screening for Patients with Pediatric Systemic Lupus Erythematosus

    Julia Harris1, Susan Parish2, Michelle Manaskie2 and Ashley Cooper2, 1Children's Mercy Kansas City, Overland Park, KS, 2Children's Mercy Kansas City, Kansas City, MO

    Background/Purpose: There is a profound need to improve outcomes in children with systemic lupus erythematosus (SLE) given this disease is complicated by significant morbidity. Disparities…
  • Abstract Number: 0433 • ACR Convergence 2025

    In-hospital outcomes of patients admitted due to First-Time Pulmonary Embolism with preexisting Rheumatoid Arthritis: A Nationwide Analysis 2016-2022

    John Langley1, Karuna Bista2, Clarisse Yapp2, Nisha Sapkota3, Shukranta Shrestha2 and Sulav Pyakurel1, 1Montefiore New Rochelle Hospital, New Rochelle, NY, 2Montefiore New Rochelle Hospital, New Rochelle, 3Interfaith Medical Center, One Brooklyn Health, Brooklyn, NY

    Background/Purpose: Although it has been documented that patients with Rheumatoid Arthritis may be at increased risk of Pulmonary Embolism, other inpatient outcomes remain largely unexplored.…
  • « Previous Page
  • 1
  • …
  • 37
  • 38
  • 39
  • 40
  • 41
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology